TMDX

TMDX

USD

TransMedics Group Inc. Common Stock

$121.176+0.866 (0.719%)

Preço em tempo real

Healthcare
Dispositivos médicos
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$120.310

Máximo

$125.220

Mínimo

$119.000

Volume

1.03M

Fundamentos da empresa

Capitalização de mercado

4.1B

Setor

Dispositivos médicos

País

United States

Estatísticas de negociação

Volume médio

1.00M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $55Atual $121.176Máximo $145.5

Notícias relacionadas

PR Newswire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Ver mais
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and raises the price target from $142 to $147.

Ver mais
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
Analyst Upgrades

Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140

Piper Sandler analyst Matt O'Brien maintains TransMedics Group with a Overweight and lowers the price target from $145 to $140.

Ver mais
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
Analyst Upgrades

Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target

Needham analyst Mike Matson upgrades TransMedics Group from Hold to Buy and announces $148 price target.

Ver mais
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and maintains $142 price target.

Ver mais
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
Analyst Upgrades

Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145

Jefferies analyst Young Li initiates coverage on TransMedics Group with a Buy rating and announces Price Target of $145.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.